• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»AI in pathology

Ibex–HNL Lab Medicine deal signals shift from digital pathology to embedded AI decision support in U.S. diagnostics

By Pallavi Madhiraju on March 22, 2026   Medical Devices & Diagnostics  

Ibex–HNL Lab Medicine deal signals shift from digital pathology to embedded AI decision support in U.S. diagnostics

Ibex partners with HNL Lab Medicine to deploy AI in prostate cancer diagnostics. Discover what this means for pathology workflows and adoption.

Fulgent Genetics acquires Bako Diagnostics and StrataDx to offset precision diagnostics headwind

By Pallavi Madhiraju on March 19, 2026   Medical Devices & Diagnostics  

Fulgent Genetics acquires Bako Diagnostics and StrataDx to offset precision diagnostics headwind

Fulgent Genetics closes $56.9M Bako and StrataDx acquisition. What it means for anatomic pathology growth, margin risk, and diagnostic consolidation in 2026.

Can Agilent’s new slide scanner system shift digital pathology from pilot to mainstream in Europe?

By Pallavi Madhiraju on January 24, 2026   Medical Devices & Diagnostics  

Can Agilent’s new slide scanner system shift digital pathology from pilot to mainstream in Europe?

Agilent’s new S540MD slide scanner targets scale and AI integration in European pathology labs. Find out what this means for digitisation strategy.

Recent Posts

  • Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?
  • Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves
  • Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?
  • Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
  • AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes